echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ARD: Over 30,000 Data Study: Efficacy of TNF Inhibitors, Abatacept, IL6 Inhibitors, and JAK Inhibitors in Patients with Rheumatoid Arthritis

    ARD: Over 30,000 Data Study: Efficacy of TNF Inhibitors, Abatacept, IL6 Inhibitors, and JAK Inhibitors in Patients with Rheumatoid Arthritis

    • Last Update: 2022-09-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: Several second-line treatment options are available to rheumatologists and patients for patients with rheumatoid arthritis who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs) or who have contraindications


    Methods: In this observational cohort study, patients initiated on tumor necrosis factor inhibitors (TNFi), interleukin-6 inhibitors (IL-6i), abatacept (ABA), or JAKi were included


    RESULTS: A total of 31,846 courses were included in the study: 17,522 TNFi, 2,775 ABA, 3,863 IL-6i, and 7,686 JAKi


    CONCLUSIONS: JAKi- and IL-6i-adjusted overall discontinuation rates and 1-year remission rates were similar to those observed with TNFi


    Source: Lauper K, Iudici M, Mongin D, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.